- Home
- SOWG vs KZIA Comparison
SOWG vs KZIA Comparison
Compare SOWG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- KZIA
- Stock Information
- Founded
- SOWG 2010
- KZIA 1994
- Country
- SOWG United States
- KZIA Australia
- Employees
- SOWG N/A
- KZIA N/A
- Industry
- SOWG Packaged Foods
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- KZIA Health Care
- Exchange
- SOWG Nasdaq
- KZIA Nasdaq
- Market Cap
- SOWG 10.1M
- KZIA 9.0M
- IPO Year
- SOWG N/A
- KZIA 1999
- Fundamental
- Price
- SOWG $0.83
- KZIA $6.65
- Analyst Decision
- SOWG
- KZIA Strong Buy
- Analyst Count
- SOWG 0
- KZIA 3
- Target Price
- SOWG N/A
- KZIA $16.00
- AVG Volume (30 Days)
- SOWG 257.4K
- KZIA 188.8K
- Earning Date
- SOWG 11-12-2025
- KZIA 11-14-2025
- Dividend Yield
- SOWG N/A
- KZIA N/A
- EPS Growth
- SOWG N/A
- KZIA N/A
- EPS
- SOWG N/A
- KZIA N/A
- Revenue
- SOWG $9,271,376.00
- KZIA $1,549,158.00
- Revenue This Year
- SOWG $6.81
- KZIA N/A
- Revenue Next Year
- SOWG N/A
- KZIA $49.25
- P/E Ratio
- SOWG N/A
- KZIA N/A
- Revenue Growth
- SOWG N/A
- KZIA 248983.08
- 52 Week Low
- SOWG $0.51
- KZIA $2.86
- 52 Week High
- SOWG $11.34
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- SOWG 54.02
- KZIA 42.44
- Support Level
- SOWG $0.70
- KZIA $6.82
- Resistance Level
- SOWG $1.01
- KZIA $7.39
- Average True Range (ATR)
- SOWG 0.08
- KZIA 0.44
- MACD
- SOWG 0.01
- KZIA 0.01
- Stochastic Oscillator
- SOWG 44.84
- KZIA 18.33
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.